# Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

> **NCT04142931** · PHASE1 · UNKNOWN · sponsor: **Dr. Ronnie Shapira** · enrollment: 30 (estimated)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer
- Stage IV Melanoma
- Triple Negative Breast Cancer
- Renal Cell Carcinoma Stage IV

## Interventions

- **COMBINATION_PRODUCT:** ImmunicomAIAC

## Key facts

- **NCT ID:** NCT04142931
- **Lead sponsor:** Dr. Ronnie Shapira
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-24
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142931, "Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04142931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*